Spruce Biosciences, Inc. Common Stock Total Assets
Spruce Biosciences, Inc. Common Stock total assets. Based on the latest financial reports, Spruce Biosciences, Inc. Common Stock (SPRB) holds total assets worth $102.85 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Spruce Biosciences, Inc. Common Stock for the company's overall valuation and market capitalisation.
Total Assets of Spruce Biosciences, Inc. Common Stock (2018–2025)
Total assets of Spruce Biosciences, Inc. Common Stock from 2018 to 2025. This chart illustrates how Spruce Biosciences, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Spruce Biosciences, Inc. Common Stock share price for real-time trading data and today's change.
Spruce Biosciences, Inc. Common Stock - Asset Composition Analysis
Spruce Biosciences, Inc. Common Stock Total Assets Breakdown (December 2025)
Spruce Biosciences, Inc. Common Stock total assets breakdown as of December 2025. Spruce Biosciences, Inc. Common Stock's total assets of $102.85 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Spruce Biosciences, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Spruce Biosciences, Inc. Common Stock (SPRB) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Spruce Biosciences, Inc. Common Stock's current assets represent 98.3% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 92.2% of total assets in 2025, up from 86.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Spruce Biosciences, Inc. Common Stock Competitors by Total Assets
Key competitors of Spruce Biosciences, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Spruce Biosciences, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.23 | 2.60 | 10.37 |
| Quick Ratio | 9.23 | 2.60 | 10.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $90.19 Million | $12.89 Million | $84.86 Million |
Spruce Biosciences, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Spruce Biosciences, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.86 |
| Latest Market Cap to Assets Ratio | 2.53 |
| Asset Growth Rate (YoY) | 17.3% |
| Total Assets | $53.02 Million |
| Market Capitalization | $133.96 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Spruce Biosciences, Inc. Common Stock's assets at a significant premium (2.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Spruce Biosciences, Inc. Common Stock's assets grew by 17.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Spruce Biosciences, Inc. Common Stock (2018–2025)
The table below shows the annual total assets of Spruce Biosciences, Inc. Common Stock from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $53.02 Million | +17.28% |
| 2024-12-31 | $45.21 Million | -56.51% |
| 2023-12-31 | $103.95 Million | +21.36% |
| 2022-12-31 | $85.65 Million | -32.29% |
| 2021-12-31 | $126.49 Million | -22.35% |
| 2020-12-31 | $162.88 Million | +3371.50% |
| 2019-12-31 | $4.69 Million | -1.74% |
| 2018-12-31 | $4.78 Million | -- |
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating… Read more